The website change is immaterial for trading. The relevant event is the $37.2M dilutive offering priced at $15.50/ADS with warrants, which creates ~24% dilution overhang relative to pre-offering shares. Monitor for clinical trial catalysts (paxalisib) that could offset dilution sentiment.
Price Chart
Executive Summary
Kazia Therapeutics filed a routine 6-K announcing the launch of a new website (www.kaziatx.com) and an updated URL. The filing is purely administrative with no financial or operational disclosures. However, the same day a $37.2M dilutive offering (424B5) was priced, making the 6-K's incorporation-by-reference into the shelf registration a technical step supporting that capital raise.
Key Facts
- Launched new website at www.kaziatx.com on August 28, 2026
- Prior URL www.kaziatherapeutics.com will redirect to the new site
- 6-K incorporates by reference into existing F-3 registration statements (Nos. 333-276091, 333-281937, 333-294392)
- No financial data, clinical updates, or material business changes disclosed
Financial Impact
No financial impact from the website launch itself; the concurrent $37.2M offering (424B5) is the material capital event
Risk Factors
- Dilution from the $37.2M offering (2.28M ADS + warrants) pressures near-term valuation
- No clinical or pipeline updates in this filing; reliance on upcoming trial readouts for upside
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-095348 |
| Document: 0001213900-26-095348-index-headers.html | 0001213900-26-095348 |
| Document: 0001213900-26-095348-index.html | 0001213900-26-095348 |
| Document: 0001213900-26-095348.txt | 0001213900-26-095348 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 24d ago | SC 13G/A | $9.27 | awaiting T+20 | — | $7.87 (−15.10%) |
Sep 22, 2026 4w ago | 6-K | $10.92 $7.88 | ▼ −27.84% | ▼ −27.28% | $7.87 (−27.93%) |
Sep 1, 2026 7w ago | 6-K | $12.61 $9.60 | ▼ −23.91% | ▼ −23.58% | $7.87 (−37.59%) |
Aug 31, 2026 7w ago | Press Release | $12.63 $9.60 | ▲ +24.03% | ▲ +24.35% | $7.87 (+37.69%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▼ −29.19% | ▼ −29.01% | $7.87 (−42.85%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $7.87 (+42.85%) |
Aug 31, 2026 8w ago | 424B5 | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $7.87 (+42.85%) |
Aug 28, 2026 8w ago | 6-K / 424B5 | $13.58 $9.60 | ▲ +29.31% | ▲ +29.57% | $7.87 (+42.05%) |
Aug 28, 2026 8w ago | 424B5 | $13.58 $9.60 | ▼ −29.31% | ▼ −29.57% | $7.87 (−42.05%) |
Jul 28, 2026 12w ago | 6-K | $12.69 $13.79 | ▲ +8.67% | ▲ +5.29% | $7.87 (−37.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers